Growth Hormone Deficiency Market Size

Growth Hormone Deficiency Market size was valued at USD 4.51 billion in 2023 and is expected to reach USD 7.23 billion by 2036, registering around 3.7% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of growth hormone deficiency is assessed at USD 4.64 billion.

Growth Hormone stimulates the growth of all essential tissues of the human body, including bone. Growth hormone deficiency (GHD) is a disorder that is caused due to the lack of growth hormones and is caused when the pituitary gland doesn’t produce enough concentration of human growth hormone also referred to as somatotropin. Several genetic disorders, such as Prader-Willi syndrome and Turner syndrome, might also be the reason for growth hormone deficiency in humans, leading to late puberty and shorter-than-average height. The condition can follow at any stage in a person’s life and treatments comprise growth hormone injections to stimulate growth.

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of growth hormone deficiency is assessed at USD 4.64 billion.

Growth Hormone Deficiency Market size was valued at USD 4.51 billion in 2023 and is expected to reach USD 7.23 billion by 2036, registering around 3.7% CAGR during the forecast period i.e., between 2024-2036.

North America industry is expected to hold largest revenue share by 2036, attributed to factors such as high healthcare expenditure, and amplified intake of human growth hormone therapies in the region in order to cure different syndromes such as Turner syndrome.

The major players in the market are Merck KGaA, Teva Pharmaceuticals Industries Ltd., Ipsen Pharma Biotech SAS, Novartis AG, Pfizer, Inc., F. Hoffmann-La Roche Ltd, Ferring B.V., Novo Nordisk A/S, Eli Lilly and Company, AnkeBio Co., Ltd, and others.

Growth Hormone Deficiency Market Size